Loring Wolcott & Coolidge Fiduciary Advisors’s Epizyme, Inc EPZM Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-3,000	Closed	-$37K	–	779
2019 Q1	$37K	Hold	3,000	–	–	﹤0.01%	436
2018 Q4	$18K	Hold	3,000	–	–	﹤0.01%	532
2018 Q3	$32K	Hold	3,000	–	–	﹤0.01%	458
2018 Q2	$41K	Hold	3,000	–	–	﹤0.01%	450
2018 Q1	$53K	Hold	3,000	–	–	﹤0.01%	439
2017 Q4	$38K	Hold	3,000	–	–	﹤0.01%	465
2017 Q3	$57K	Hold	3,000	–	–	﹤0.01%	417
2017 Q2	$34K	Hold	3,000	–	–	﹤0.01%	450
2017 Q1	$51K	Hold	3,000	–	–	﹤0.01%	409
2016 Q4	$36K	Hold	3,000	–	–	﹤0.01%	423
2016 Q3	$30K	Hold	3,000	–	–	﹤0.01%	445
2016 Q2	$31K	Sell	3,000 -2,500	-45%	-$27.9K	﹤0.01%	443
2016 Q1	$67K	Buy	5,500 +3,000	+120%	+$30.3K	﹤0.01%	360
2015 Q4	$40K	Hold	2,500	–	–	﹤0.01%	447
2015 Q3	$60K	Hold	2,500	–	–	﹤0.01%	404
2015 Q2	$60K	Hold	2,500	–	–	﹤0.01%	404
2015 Q1	$47K	Hold	2,500	–	–	﹤0.01%	440
2014 Q4	$47K	Buy	+2,500	New	+$58.4K	﹤0.01%	433

Other funds holding EPZM

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's EPZM Position: Q2 2019 in Review

Loring Wolcott & Coolidge Fiduciary Advisors sold out of Epizyme, Inc (EPZM) in Q2 2019, closing a stake of 3,000 shares — an estimated $37K sold.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in EPZM in Q4 2014 and held it in 18 quarters. The position peaked at $67K in Q1 2016. 134 funds tracked by Wall St. Rank hold EPZM as of Q2 2019.

Loring Wolcott & Coolidge Fiduciary Advisors reported no remaining Epizyme, Inc position as of Q2 2019 after selling out during the quarter.
Loring Wolcott & Coolidge Fiduciary Advisors sold 3,000 Epizyme, Inc shares in Q2 2019, an estimated $37K.
Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Epizyme, Inc in Q4 2014 and held it in 18 quarters.
Loring Wolcott & Coolidge Fiduciary Advisors's Epizyme, Inc position peaked at $67K in Q1 2016.
134 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2019.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q2 2019, filed 9 Aug 2019.